What does the future of hearing restoration look like? Are we approaching a world where hearing loss can be treated with pharmaceuticals rather than simply managed with hearing aids? Originally presented at the Future of Hearing Healthcare (FHH2026) conference, this expert panel explores the latest advances in inner ear therapeutics and what they could mean for the future of hearing healthcare....
No actionable change — this is a conference panel discussion presenting the landscape of emerging inner ear therapeutics; no clinical trials have yet produced practice-ready interventions for audiologists to adopt.
Pharmaceutical and biological therapies for inner ear hearing loss represent a potential paradigm shift beyond amplification, and audiologists should begin building awareness of the pipeline so they can counsel patients and adapt their practice when treatments reach clinical availability.
- 01Expert panel from FHH2026 conference surveys the future of inner ear drug and biological therapies for hearing loss.
- 02Approaches discussed go beyond conventional hearing aid management, targeting the underlying biology of hearing loss.
- 03Both pharmaceutical (small-molecule drugs) and biological (gene therapy, cell therapy) strategies are in the pipeline.
- 04Content is forward-looking and based on expert opinion rather than completed clinical trials.
- 05Audiologists are positioned as key stakeholders as these therapies move toward clinical translation.
Pharmaceutical and biological approaches can treat hearing loss beyond what conventional hearing aids offer.
opinionunclearInner ear therapeutics represent the future of hearing loss management.
opinionpartially supported